Information Provided By: 
Fly News Breaks for January 27, 2020
RLMD
Jan 27, 2020 | 04:54 EDT
Jefferies analyst Andrew Tsai initiated coverage of Relmada Therapeutics with a Buy rating and $75 price target.
News For RLMD From the Last 2 Days
RLMD
Apr 25, 2024 | 10:57 EDT
In this week's "Rising High," The Fly's recurring series focused on cannabis and psychedelic stock news, The Fly looks back on study dosing, a completed acquisition and a research partnership. ATAI ANNOUNCES DOSING... To see the rest of the story go to thefly.com. See Story Here
